Viagra Pharmacokinetics (ADME): How Sildenafil Is Absorbed, Distributed, Metabolized, and Excreted

What Is Sildenafil and Why Does Its Pharmacokinetics Matter?

Sildenafil is an oral phosphodiesterase type 5 (PDE5) inhibitor first approved by the FDA in March 1998 for erectile dysfunction (ED). Goldstein et al. Published the landmark trial in the New England Journal of Medicine that same year, demonstrating dose-dependent improvements in erectile function across 532 men over 24 weeks. Understanding the drug's absorption, distribution, metabolism, and excretion (ADME) profile is not merely academic. Dose selection, meal timing, drug interactions, and dose adjustments in renal or hepatic impairment all flow directly from these parameters.

Why ADME Determines Clinical Dosing Windows

The 30-to-60-minute pre-activity recommendation printed on every prescription label traces directly to the drug's Tmax of 30 to 120 minutes. Miss that window in either direction and tissue concentrations at the corpus cavernosum may be subtherapeutic at the moment they are needed. The FDA-approved label for sildenafil specifies that the drug should be taken approximately one hour before sexual activity, but clinical flexibility extends from 30 minutes to 4 hours based on individual pharmacokinetic variability [1].

Sildenafil vs. Pulmonary Hypertension Dosing

The same molecule is sold as Revatio (20 mg three times daily) for pulmonary arterial hypertension (PAH). The ED dose (25 to 100 mg on demand) and the PAH dose target different tissue compartments. Systemic PDE5 inhibition for PAH requires sustained plasma trough levels rather than a single concentration peak, which explains the three-times-daily schedule. This distinction matters when reviewing pharmacokinetic studies because some published concentration-time curves apply to multiple-dose PAH regimens, not single ED doses [2].

Absorption: Oral Bioavailability and Meal Effects

Sildenafil is absorbed through the gastrointestinal tract and reaches systemic circulation with an absolute oral bioavailability of approximately 41%, according to the FDA prescribing information [1]. That number reflects extensive first-pass hepatic extraction despite rapid GI uptake.

Fasted vs. Fed State

A high-fat meal delays Tmax by roughly 60 minutes and reduces Cmax by approximately 29% without meaningfully changing total exposure (AUC) [1]. The clinical implication: patients who take sildenafil after a fatty meal may notice slower onset and a blunted peak effect. For men who report the drug "doesn't work," meal timing is one of the first variables worth reassessing.

Tmax Variability

Tmax spans 30 to 120 minutes across healthy volunteers. Age, gastric motility, and concurrent medications all shift that window. One pharmacokinetic study in healthy male volunteers found median Tmax of 60 minutes under fasted conditions, with individual values ranging from 30 to 90 minutes [3]. That spread alone explains much of the patient-reported variability in time-to-effect.

Sublingual and Other Routes

Sublingual sildenafil has been studied as a faster-onset alternative. A crossover study (N=14) found sublingual sildenafil 25 mg reached Tmax in approximately 15 minutes versus 40 minutes for the equivalent oral tablet, with comparable AUC [4]. This route is not FDA-approved for ED but is discussed in urology literature as an option for patients who need faster onset.

Distribution: Where Sildenafil Goes After Absorption

Once in systemic circulation, sildenafil distributes broadly. The steady-state volume of distribution is approximately 105 L, indicating distribution well beyond the plasma compartment into peripheral tissues [1]. The corpus cavernosum, lung vasculature, and retinal photoreceptors all express PDE5, explaining both the therapeutic effect and the side-effect profile (blue-tinge visual disturbance at higher doses).

Plasma Protein Binding

Sildenafil binds approximately 96% to plasma proteins, primarily albumin and alpha-1-acid glycoprotein [1]. Only the free (unbound) fraction is pharmacologically active. Conditions that reduce albumin, such as cirrhosis or severe malnutrition, may increase free drug concentrations and amplify both efficacy and adverse effects at standard doses.

Blood-Brain Barrier and CNS Penetration

Sildenafil does cross the blood-brain barrier to a limited degree. Animal studies and human case reports have documented CNS effects at supratherapeutic doses, including headache (reported in ~16% of patients in clinical trials) [1]. The drug's role in PDE5-mediated signaling within the brain is an active area of research, though it is not currently the basis for any approved CNS indication.

Tissue-Level PDE5 Expression and Drug Effect

PDE5 is expressed at highest density in vascular smooth muscle, platelets, and lung parenchyma. In the penis, PDE5 hydrolyzes cyclic GMP (cGMP), terminating smooth muscle relaxation and reducing blood inflow. Sildenafil's inhibition of PDE5 preserves cGMP, allowing the smooth muscle relaxation initiated by nitric oxide (NO) to persist [5]. The selectivity of sildenafil for PDE5 over PDE6 (retinal) is approximately 10-fold, which accounts for the transient visual symptoms seen at higher doses [1].

Mechanism of Action: PDE5 Inhibition at the Molecular Level

Sildenafil's mechanism connects directly to its pharmacokinetics because tissue exposure, not just plasma concentration, drives effect. Understanding both layers together gives clinicians a complete picture.

The NO-cGMP-PDE5 Axis

Sexual stimulation triggers release of nitric oxide (NO) from non-adrenergic, non-cholinergic (NANC) neurons and endothelial cells in the corpus cavernosum. NO activates guanylate cyclase, raising intracellular cGMP. Elevated cGMP opens potassium channels and closes calcium channels in smooth muscle, causing relaxation, arterial dilation, and penile tumescence [5]. PDE5 terminates this signal by degrading cGMP to 5-GMP. Sildenafil occupies the catalytic site of PDE5 competitively, slowing cGMP breakdown and extending the erectile response to stimulation.

Why Sildenafil Requires Sexual Stimulation

This is a common patient question. Sildenafil does not generate an erection in the absence of sexual stimulation because it acts downstream of NO release, not upstream. Without the initial NO signal from arousal, cGMP levels do not rise enough for PDE5 inhibition to produce a meaningful effect. This mechanistic point, derived from the original Goldstein et al. Trial [6] and confirmed in subsequent pharmacodynamic studies, distinguishes PDE5 inhibitors from centrally acting agents such as apomorphine.

Selectivity Profile Across PDE Isoforms

Sildenafil is approximately 10-fold selective for PDE5 over PDE6, 80-fold selective over PDE1, and greater than 700-fold selective over PDE2, PDE3, and PDE4 [1]. The relative lack of selectivity over PDE6 (found in retinal rods and cones) explains the blue-tinge visual disturbance reported by approximately 3% of patients in trials [1]. PDE3 inhibition, which would cause cardiac inotropy, is minimal at therapeutic doses.

Metabolism: Hepatic CYP Enzymes and the Active Metabolite

Sildenafil undergoes extensive hepatic first-pass metabolism. The primary pathway is N-demethylation by CYP3A4, producing the active metabolite N-desmethyl-sildenafil (also designated UK-103,320) [1]. A secondary pathway involves CYP2C9.

N-Desmethyl-Sildenafil (UK-103,320)

The active metabolite reaches plasma concentrations approximately 40% of the parent compound at steady state. Its PDE5 selectivity is roughly 50% that of sildenafil, so it contributes meaningfully to the overall pharmacodynamic effect, particularly in patients who are rapid CYP3A4 metabolizers [1]. The metabolite's terminal half-life is similar to the parent drug, approximately 4 hours, meaning the two compounds clear in parallel rather than the metabolite accumulating.

CYP3A4 Drug Interactions: A Clinically Critical Issue

Strong CYP3A4 inhibitors dramatically increase sildenafil exposure. Co-administration with ritonavir (a potent CYP3A4 and CYP2C9 inhibitor used in HIV therapy) raised sildenafil AUC by 11-fold in a dedicated interaction study [1]. The FDA label therefore contraindicates doses above 25 mg of sildenafil within 48 hours of ritonavir. Similar, though less extreme, interactions occur with ketoconazole, itraconazole, erythromycin, and clarithromycin.

CYP3A4 inducers move in the opposite direction. Rifampicin (600 mg once daily) reduced sildenafil AUC by 87% in healthy volunteers [7]. Patients on chronic rifampicin therapy for tuberculosis may receive essentially no therapeutic sildenafil exposure at standard doses, requiring alternative ED management strategies.

CYP2C9 Interactions

The CYP2C9 pathway is a minor contributor under normal circumstances. CYP2C9 poor metabolizers, estimated at 3 to 5% of European populations, may show modestly elevated sildenafil concentrations [8]. Clinicians prescribing sildenafil to patients already on warfarin (a CYP2C9 substrate) should note the theoretical competition, though clinically significant coagulation changes have not been consistently reported in trials.

Hepatic Impairment Dose Adjustments

Because hepatic CYP enzymes handle nearly all sildenafil clearance, hepatic impairment substantially raises exposure. In patients with Child-Pugh Class A or B cirrhosis, sildenafil AUC increased by 84% compared to healthy controls [1]. The FDA label recommends starting at 25 mg in this population. Child-Pugh Class C cirrhosis data are limited, and use requires clinical judgment.

Excretion: Routes, Half-Life, and Renal Impairment

Sildenafil and its metabolites exit the body predominantly through feces. Approximately 80% of a radiolabeled oral dose appears in feces and approximately 13% in urine, almost entirely as metabolites [1]. Less than 0.001% of the parent drug is excreted unchanged in urine, confirming that renal clearance of the unmetabolized compound is negligible.

Terminal Half-Life

The terminal elimination half-life of sildenafil is 3 to 5 hours in healthy young men [1]. The active metabolite shares a similar half-life, so clinically effective exposure persists for 4 to 6 hours post-dose. This aligns with patient-reported windows of efficacy of 4 to 5 hours in real-world use, though individual variation is substantial.

Renal Impairment

Renal impairment does not substantially alter sildenafil pharmacokinetics because renal excretion of the parent compound is minimal. A pharmacokinetic study in patients with severe renal impairment (creatinine clearance <30 mL/min) found sildenafil AUC approximately 100% higher than in matched healthy controls, attributable to reduced renal clearance of the circulating metabolites rather than the parent drug [1]. The FDA label recommends starting at 25 mg in patients with severe renal impairment.

Age-Related Changes

Healthy elderly volunteers (65 years and older) showed sildenafil AUC and Cmax approximately 90% higher than in younger men, with reduced clearance attributed to decreased hepatic CYP3A4 activity and reduced renal function [1]. Starting doses of 25 mg are therefore recommended in men over 65, with upward titration guided by tolerability and response.

Special Populations and Pharmacokinetic Variability

The following framework organizes dose-adjustment decisions by pharmacokinetic mechanism, helping clinicians apply the underlying science rather than memorizing each scenario separately.

Framework: Mechanism-Based Dose Adjustment for Sildenafil

| Population | PK Mechanism | Expected AUC Change | Label Recommendation | |---|---|---|---| | Strong CYP3A4 inhibitor (e.g., ritonavir) | Reduced CYP3A4 clearance | Up to +1,100% | Max 25 mg per 48 hours | | CYP3A4 inducer (e.g., rifampicin) | Increased CYP3A4 clearance | Up to -87% | Consider alternative ED therapy | | Child-Pugh A/B cirrhosis | Reduced hepatic first-pass | +84% | Start 25 mg | | Severe renal impairment (CrCl <30 mL/min) | Reduced metabolite clearance | ~+100% | Start 25 mg | | Age 65+ | Reduced hepatic and renal clearance | ~+90% | Start 25 mg | | High-fat meal | Delayed GI absorption | Cmax -29%, Tmax +60 min | Take fasted for fastest onset |

Pharmacokinetics in Women

Sildenafil is not FDA-approved for female sexual dysfunction, but it has been studied in women. A pharmacokinetic comparison found no clinically meaningful sex-based differences in AUC or Cmax after single-dose administration in healthy volunteers [9]. The clinical evidence for efficacy in women is mixed; a Cochrane review found limited evidence for benefit in premenopausal women, with insufficient data to draw conclusions in postmenopausal populations [10].

Pharmacokinetics in Pulmonary Arterial Hypertension

At the Revatio dose of 20 mg three times daily, sildenafil reaches steady state within one to two days. Steady-state Cmax is lower per dose than the 100 mg ED dose, but trough concentrations are maintained continuously. The pharmacokinetic rationale for this dosing schedule is sustained PDE5 inhibition in pulmonary vasculature rather than episodic peak-driven effect [2].

Nitrate Interaction: A Pharmacodynamic Amplification, Not a PK Interaction

The absolute contraindication to sildenafil with nitrates is pharmacodynamic rather than pharmacokinetic, but it depends on plasma sildenafil concentrations and therefore on ADME. Both nitrates and sildenafil increase cGMP in vascular smooth muscle, the former by donating NO and the latter by preventing cGMP degradation. The combination causes additive reductions in systemic vascular resistance and can produce severe, potentially fatal hypotension [1].

The American College of Cardiology and American Heart Association guidelines state that nitrates should not be administered within 24 hours of sildenafil [11]. Because the terminal half-life is 3 to 5 hours, five half-lives (approximately 15 to 25 hours) are needed for sildenafil to fall below 3% of peak plasma concentration. The 24-hour washout period is therefore based on ADME data directly. Tadalafil's longer half-life (17.5 hours) requires a 48-hour nitrate-free window, illustrating how half-life differences translate into concrete clinical rules across the PDE5 inhibitor class.

Comparing Sildenafil ADME to Other PDE5 Inhibitors

Sildenafil's pharmacokinetic profile sits between the short-acting avanafil and the long-acting tadalafil.

Tadalafil

Tadalafil has a half-life of approximately 17.5 hours, enabling once-daily dosing at 5 mg for ED and PAH [12]. Its Tmax of 2 hours is slower than sildenafil's, and food does not meaningfully affect its absorption. The extended half-life supports daily dosing for men who prefer not to plan around a dosing window.

Avanafil

Avanafil reaches Tmax in approximately 30 to 45 minutes and has a half-life of 3 to 5 hours, similar to sildenafil [13]. Its faster absorption makes it the preferred choice for patients who need the shortest possible onset time, though it carries the same nitrate contraindication.

Vardenafil

Vardenafil's ADME profile closely resembles sildenafil's: Tmax of 30 to 120 minutes, half-life of 4 to 5 hours, and CYP3A4-dominant metabolism [14]. High-fat meals do not delay vardenafil absorption to the degree seen with sildenafil, which is a minor practical advantage.

Clinical Takeaways from Sildenafil Pharmacokinetics

Pharmacokinetic data translate directly into prescribing decisions. The points below are not theoretical considerations; each connects to a concrete label recommendation or trial finding.

Timing the Dose Correctly

Taking sildenafil 60 minutes before anticipated sexual activity, in a fasted state, produces the highest and fastest Cmax. Men who report treatment failure should be asked specifically whether they ate a high-fat meal before dosing, whether they waited an adequate interval, and whether they are on CYP3A4-inhibiting medications that might require a dose reduction from 50 mg or 100 mg to 25 mg.

Identifying Drug Interactions Before Prescribing

The single most dangerous pharmacokinetic interaction is co-prescription with nitrates, driven by pharmacodynamic amplification at whatever plasma concentration sildenafil reaches. The second-highest-risk category is CYP3A4 inhibitors, particularly ritonavir and other HIV protease inhibitors, which can raise AUC by up to 1,100% [1]. A medication reconciliation check for nitrates and strong CYP3A4 inhibitors should precede every sildenafil prescription.

Adjusting for Age and Organ Function

The 25 mg starting dose in men over 65, in hepatic impairment, and in severe renal impairment is not a precautionary formality. It reflects measured AUC increases of 84% to 100% above baseline in each of these populations [1]. Starting at the full 50 mg in these groups exposes patients to concentrations equivalent to 90 to 100 mg in a healthy young adult.

The NEJM landmark trial by Goldstein et al. (N=532, 24-week duration) used doses of 25, 50, and 100 mg and demonstrated that higher doses produced greater erectile function scores on the International Index of Erectile Function (IIEF), with 69% of all attempts at intercourse successful in the 100 mg group versus 22% with placebo (P<0.001) [6]. The dose-response relationship observed in that trial is a direct reflection of the exposure-response relationship inherent in the drug's pharmacokinetics.